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Abstract
Objectives: We characterized two new CTX-M-type extended-spectrum b-lactamase (ESBL) variants in Escherichia coli
isolates from stool samples of two elderly patients admitted at the Tel Aviv Sourasky Medical Center, Israel. Both patients
underwent treatment with cephalosporins prior to isolation of the E. coli strains.
Methods: ESBLs were detected by the double-disk synergy test and PCR-sequencing of b-lactamase genes. The blaCTX-M
genes were cloned into the pCR-BluntII-TOPO vector in E. coli TOP10. The role of amino-acid substitutions V77A and D240G
was analyzed by site-directed mutagenesis of the blaCTX-M-94 and blaCTX-M-100 genes and comparative characterization of the
resulting E. coli recombinants. MICs of b-lactams were determined by Etest. Plasmid profiling, mating experiments, replicon
typing and sequencing of blaCTX-M flanking regions were performed to identify the genetic background of the new CTX-M
variants.
Results: The novel CTX-M b-lactamases, CTX-M-94 and -100, belonged to the CTX-M-25-group. Both variants differed from
CTX-M-25 by the substitution V77A, and from CTX-M-39 by D240G. CTX-M-94 differed from all CTX-M-25-group enzymes by
the substitution F119L. Glycine-240 was associated with reduced susceptibility to ceftazidime and leucine-119 with
increased resistance to ceftriaxone. blaCTX-M-94 and blaCTX-M-100 were located within ISEcp1 transposition units inserted into
,93 kb non-conjugative IncFI and ,130 kb conjugative IncA/C plasmids, respectively. The plasmids carried also different
class 1 integrons.
Conclusions: This is the first report on CTX-M-94 and -100 ESBLs, novel members of the CTX-M-25-group.
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Introduction
CTX-Ms are the most prevalent extended-spectrum b-lacta-
mases (ESBLs) in Enterobacteriaceae causing hospital- and
community-acquired infections [1–3]. The blaCTX-M genes are
usually located on plasmids, and are derivatives of chromosomal
b-lactamase genes of the Kluyvera genus due to multiple mobiliza-
tion events [1,4]. Usually, these plasmids easily spread in microbial
populations, also carrying other resistance genes such as those
coding for aminoglycoside acetyltransferases, dihydropteroate
synthases or other b-lactamases [3]. New CTX-M variants arise
rapidly and so far 131 different enzymes of this family have been
identified (http://www.lahey.org/studies). They can all be as-
signed to five different subfamilies, based on amino acid identity:
the CTX-M-1, -2, -8, -9, and -25 groups [1]. New CTX-M
variants within these groups emerge by the gradual accumulation
of mutations, some of which affect enzyme activity and resistance
phenotype, and are being selected by antibiotic pressure [5,6].
Unlike the CTX-M-1, -2 and -9 groups, the CTX-M-25-like b-
lactamases have been rarely observed worldwide [7–9]. However,
the situation in Israel is in stark contrast as a remarkable number
of CTX-M-25-group enzymes, namely CTX-M-25, -26, 39 and -
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41, have been previously reported in there [10,11]. We recently
identified two new CTX-M-25-group variants, CTX-M-94 and -
100, in Escherichia coli isolates from patients admitted at the Tel
Aviv Sourasky Medical Center, Israel. The aim of this study was to
characterize CTX-M-94 and -100 and to understand the
phylogenetic relationships between the novel and the known
CTX-M-25-group variants.
Methods
Bacterial Strains
Two E. coli clinical strains were recovered in 2008–2009 during
an epidemiological study from screening stool samples of two
elderly patients hospitalized at the Tel Aviv Sourasky Medical
Center, Israel. These isolates were identified using mass spec-
trometry (MALDI-TOF, Bruker Daltonics, Bremen, Germany).
E. coli TOP10 electrocompetent cells (Invitrogen, Carlsbad, CA,
USA) were utilized as hosts for cloning and site-directed
mutagenesis experiments, and rifampicin-resistant E. coli A15
was used as a recipient in mating tests [12].
Phenotypic ESBL Detection and Susceptibility Testing
The ESBL phenotype of the two clinical isolates was confirmed
by the double-disk synergy test using cefotaxime, ceftazidime,
cefepime and amoxicillin/clavulanate disks [13]. Susceptibility to
b-lactam antibiotics (amoxicillin, amoxicillin/clavulanate, ampi-
cillin, aztreonam, cefepime, cefotaxime, cefoxitin, ceftazidime,
ceftazidime/clavulanate, ceftriaxone, imipenem, piperacillin, and
piperacillin/tazobactam) was tested by disk diffusion (disks from
Oxoid, Basingstoke, UK) and by Etest (bioMe´rieux, Marcy
l’Etoile, France) according to the CLSI guidelines [14].
Genotypic ESBL Detection and blaCTX-M Characterization
Total DNA was extracted from the isolates by alkaline lysis as
described previously [15]. Plasmid DNA was obtained from the
isolates with the PureLink HiPure Plasmid Miniprep Kit according
to the manufacturer’s protocol (Invitrogen). b-lactamase genes
blaCTX-M, blaSHV, and blaTEM were detected by PCR using
universal primers with modified cycling conditions: 10 min at
95uC, 30 cycles of 30s at 95uC, 30s at 59uC, and 1 min at 72uC,
and 10 min at 72uC [16–18]. The entire blaCTX-M-94 and blaCTX-
M-100 genes were amplified using previously described primers
CTX-M-25-F (specific for the ISEcp1 element) and CTX-M-25-R
primers with modified cycling conditions: 10 min at 95uC, 30
cycles of 30 s at 95uC, 30 s at 55uC, and 1.5 min at 72uC, and
10 min at 72uC [10]. The amplicons were sequenced directly on
both strands, compared to known blaCTX-M sequences (GenBank
and Lahey Clinic), and analyzed using BLASTn (NCBI, http://
www.ncbi.nlm.nih.gov) and the Lasergene software (DNASTAR,
Madison, WI, USA). The extrachromosomal location of blaCTX-M-
94 and blaCTX-M-100 was confirmed by amplification from plasmid
DNA in triplicate, as well as by plasmid electroporation into E. coli
TOP10.
AmpC Detection
Production of AmpC-like b-lactamases was assessed by the
combination disk test with cefotaxime and ceftazidime disks, with
and without phenylboronic acid (20 ml of 20 mg/mL solution per
disk). A$5 mm increase in zone diameter after addition of
boronate indicated the higher-level expression of AmpC. Genes
coding for acquired AmpC types were identified by PCR-
sequencing analysis on plasmid DNA with target-specific primer
pairs [19].
Strain Typing and Phylogrouping
Sequence types (STs) of the E. coli strains were determined by
multilocus sequence typing (MLST) [20], using the MLST
database at the ERI, University College Cork (http://mlst.ucc.
ie/mlst/dbs/Ecoli). Phylogenetic grouping was performed by PCR
[21].
Detection of Enzymatic Activity and Isoelectric Focusing
of b-lactamases
The presence of functional b-lactamases was evidenced by a
qualitative method utilizing the chromogenic cephalosporin
nitrocefin (Calbiochem, Merck Chemicals, Nottingham, UK).
Hydrolysis of nitrocefin by b-lactamases results in a distinct colour
shift from yellow (lmax = 390 nm at pH 7.0) to red (lmax = 486 nm
at pH 7.0). A nitrocefin solution (500 mg/L) was added to crude
bacterial sonicates to show presence of functional b-lactamases.
Sonicates positive for b-lactamase activity were subjected to
isoelectric focusing (IEF) as described previously [12], in a Model
111 Mini IEF Cell (Bio-Rad, Hercules, CA, USA) The IEF gel was
homogeneously covered with the nitrocefin solution to mark all
bands corresponding to the different b-lactamases present in the
bacterial cell extracts.
Cloning of blaCTX-M genes
Blunt-ended amplicons consisting of blaCTX-M genes and
,30 bp upstream regions were produced using Platinum Pfx
DNA Polymerase (Invitrogen) and the primer pair CTX-M-25-F/
R with modified cycling conditions: 10 min at 94uC, 30 cycles of
15 s at 94uC, 30 s at 55uC, and 1.5 min at 68uC, and 10 min at
68uC. PCR products were cloned into the pCR-BluntII-TOPO
vector (Invitrogen), electrotransformed into E. coli TOP10, and
selected on LB agar supplemented with kanamycin (50 mg/L) and
cefotaxime (2 mg/L). Transformants (pCR-CTX-M-94 and -100)
were screened for presence of the blaCTX-M genes by PCR and
sequencing using M13 primers according to the manufacturer’s
protocol.
Site-directed Mutagenesis
Single point mutations were introduced into pCR-CTX-M-94
and -100 with the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s
protocol. Mutagenic primer pairs (available on request) were
designed to replace alanine at position 77 with valine (A77V) and
glycine at position 240 with aspartic acid (G240D). The
mutagenized pCR-CTX-M-94 and -100 plasmids were electro-
transformed into E. coli TOP10 and their susceptibility profiles to
b-lactams were screened by Etest.
Plasmid Typing
Total plasmid DNA obtained from the clinical isolates was
electroporated into E. coli TOP10 to separate coexisting multiple
plasmids. Unique plasmids were identified by screening the
transformants for presence of bla genes, including blaCTX-M,
blaTEM and blaCMY-2, by PCR. Plasmid profiles of the transfor-
mants carrying unique plasmids were determined by restriction
digestion of their plasmid DNA with HpaI (New England Biolabs,
Ipswich, MA, USA). Restriction products were separated along
with a 1 Kb DNA Extension Ladder (Invitrogen) on a 0.7%
agarose gel for 10 h at 2.5 V/cm with 0.5x Tris-borate-EDTA
buffer. Plasmid sizes were estimated by relative mobility calcula-
tions. Presence of bla genes was confirmed by hybridization with
blaCTX-M-25-group-, blaTEM- and blaCMY-2-specific DIG-labeled
probes and a DIG Luminescent Detection Kit (Roche Applied
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Science, Indianapolis, IN, USA) according to the manufacturer’s
protocols. Replicon types of all unique plasmids were identified by
PCR-based replicon typing as described previously [22]. Conju-
gation was carried out as described previously [12], utilizing the
clinical strains producing CTX-M-94 and -100 as donors and
rifampicin-resistant E. coli A15 strain as a recipient. Transconju-
gants were selected on LB agar with cefotaxime (2 mg/L) and
rifampicin (128 mg/L), and confirmed by the phenotypic disk
tests, PCR of bla genes, and MLST against the donors and
recipient. Transfer efficiencies were calculated based on the ratio
of CFUs/mL of transconjugants per donor cell.
Nucleotide Sequence Accession Numbers
blaCTX-M-94 and blaCTX-M-100 nucleotide sequences were
assigned GenBank accession numbers HM167760 and
FR682582, respectively.
Results and Discussion
E. coli Isolates Harbouring Novel CTX-M Variants
We recovered the CTX-M-94 and -100-producing E. coli strains
from screening stool samples of two elderly hospitalized patients.
The patients received various antibiotics, including cephalosporins
(ceftriaxone), b-lactam/inhibitor combinations (piperacillin/tazo-
bactam), cephamycins and carbapenems (imipenem). The CTX-
M-94-producing E. coli belonged to ST131 and phylogroup B2.
ST131 is a uropathogenic clone that has spread worldwide, usually
associated with ESBLs, in particular with CTX-M-15 of the CTX-
M-1 group [3,23,24]. Along with CTX-M-94, the E. coli isolate
also harboured two other acquired b-lactamases, TEM-1 and the
AmpC-like cephalosporinase CMY-2. The CTX-M-100-produc-
ing E. coli belonged to ST88 (clonal complex ST23) and
phylogroup A. Strains belonging to phylogroup A are generally
more common in the intestinal flora, and both the complex ST23
and the clone ST88 belong to the globally spread members of the
phylogroup [25]. The CTX-M-100-harbouring isolate did not
express any other acquired b-lactamase.
MICs of b-lactams for the CTX-M-94- and -100-producing
isolates are shown in Table 1. The CTX-M-94 harbouring isolate
exhibited four- to approximately 200-fold higher MICs of
amoxicillin/clavulanate, cefoxitin, cefotaxime, ceftriaxone, ceftaz-
idime (alone and with clavulanate), cefepime and aztreonam,
when compared to the CTX-M-100 producer. According to the
current CLSI guidelines [14], both isolates were highly resistant to
amoxicillin, ampicillin, piperacillin, cefotaxime and ceftriaxone,
and susceptible to piperacillin/tazobactam, cefepime and imipen-
em. The resistance pattern of the CTX-M-100-producing isolate
was similar to that of the previously described CTX-M-39-
producing E. coli from the same hospital [11], and matched well
the typical CTX-M-associated phenotype, with asymmetry in
MICs of cefotaxime and ceftazidime and good activity of inhibitor
combinations [1,5,26]. In contrast, resistance of the CTX-M-94
producer was largely influenced by CMY-2, both in level and type.
AmpC b-lactamases like CMY-2 are known to hydrolyze
cephamycins and are much less inhibited by class A enzyme
inhibitors compared to ESBLs [27], as exemplified by high MICs
of cefoxitin and clavulanate combinations, respectively (Table 1).
Furthermore, AmpC b-lactamases are also capable of hydrolyzing
oxyiminocephalosporins and monobactams, as exemplified by
elevated MICs of cefotaxime, ceftazidime, ceftriaxone and
aztreonam (Table 1). Finally, the influence of CMY-2 on the
phenotype exhibited by the wild-type CTX-M-94-harbouring
isolate was confirmed by the decreased resistance pattern of pCR-
CTX-M-94, a recombinant blaCTX-M-94-harbouring strain that
lacked CMY-2. pCR-CTX-M-94 showed a major decrease in the
MICs of cefoxitin (.256 vs. 2 mg/L), ceftazidime/clavulanate
(.4 vs. 0.25 mg/L) and cefotaxime (.256 mg/L vs. 16 mg/L),
and a more moderate decrease in the MICs of ceftriaxone (.256
vs. 48 mg/L), ceftazidime (12–16 vs. 4 mg/L) and amoxicillin/
clavulanate (8 vs. 3 mg/L).
Other differences in resistance could be attributed to molecular
differences between CTX-M-94 and -100 enzymes, which are
discussed in the following sections.
Molecular Characterization of Novel CTX-M Variants
CTX-M-94 and -100 belonged to the CTX-M-25-group,
sharing .99% homology with CTX-M-25 and -39 (Figure 1).
Both variants differed from CTX-M-25 by the substitution V77A,
and from CTX-M-39 by the substitution D240G. Additionally,
CTX-M-94 was remarkable in that it had the substitution F119L
(the only difference between CTX-M-94 and -100). This is the first
report of a CTX-M-25-group member harbouring leucine-119.
Leucine is usually present at position 119 in enzymes belonging to
CTX-M-1, -2, -8, and -9 groups, with the exception of CTX-M-11
and -85 that have proline here. Its role in resistance towards b-
lactams had not been studied before and was therefore investigat-
ed in this study by cloning experiments (see next section).
Furthermore, silent nucleotide substitutions were absent in either
blaCTX-M-94 or blaCTX-M-100 when compared with blaCTX-M-25 and
blaCTX-M-39. Genetic relatedness of all known CTX-M-25-group
enzymes, calculated using MEGA 5 (Figure 2) [28], suggested
earlier branching of the CTX-M-94 branch, possibly due to the
F119L substitution. It also indicated that CTX-M-100 is most
closely related to CTX-M-39. IEF showed double bands, with pI
values of 7.3 and 7.5, for both CTX-M-94 and -100 enzymes. A
similar pattern has been shown previously for CTX-M-39, with
pIs of 6.8 and 7.0, while CTX-M-25 has a pI of 7.5 [8,10].
Functional Characterization of Wild-type and
Mutagenized CTX-Ms
To determine the resistance patterns conferred by the new
CTX-M variants and the specific role of the F119L substitution,
blaCTX-M-94 and blaCTX-M-100 with upstream regions were cloned
in pCR-BluntII-TOPO and expressed in the isogenic background
of E. coli TOP10 (Table 1). The analysis revealed high-level
resistance towards amoxicillin, ampicillin, piperacillin, cefotaxime
and ceftriaxone for both CTX-M-94 and -100 producers without
significant differences in MIC values, except for a four-fold lower
ceftriaxone MIC in the CTX-M-100 producer (12 mg/L) when
compared to that with CTX-M-94 (48 mg/L).
To investigate the role of the V77A and D240G substitutions in
the sequence background of CTX-M-25-group b-lactamases,
reverse mutations were introduced separately into the blaCTX-M-
94 and blaCTX-M-100 genes. In CTX-M-100, the replacement of
alanine-77 with valine and glycine-240 with aspartic acid resulted
in a reproduction of the protein sequences of CTX-M-25 and -39,
respectively. When compared with CTX-M-94 and -100 wild-type
strains, the G240D revertants conferred, as expected, a remark-
able decrease in the MICs of ceftazidime (4–3 vs. 0.50–0.38 mg/
L), and a more moderate decrease in the MICs of aztreonam (4 vs.
1.50 mg/L), cefotaxime (16 vs. 4–1.50 mg/L) and ceftriaxone
(48–12 vs. 12–4 mg/L). In addition, the G240D substitution
caused a remarkable decrease in the MICs of piperacillin (.256
vs. 64 mg/L) in CTX-M-100, while having no effect in CTX-M-
94. These data fit well with previous crystallographic studies
showing that glycine-240, located in the B3 b-strand which lines
the active site, is a major contributor to ceftazidime resistance.
When aspartic acid at position 240 is replaced by glycine, the
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mobility of the B3 b-strand is increased, resulting in enhanced
protein flexibility and facilitation of hydrolysis of b-lactams with
bulkier side chains. However, this increased mobility is not only
associated with increased activity, but also with decreased stability
of the CTX-M enzyme [5,29]. A recent in vitro-evolution study
demonstrated that cefotaxime and ceftazidime probably acted as
diversifying agents in the evolution of CTX-M-1 group enzymes
[6]. One of the three distinct trajectories analyzed was the D240G
route wherein CTX-Ms carrying glycine-240 exhibited moderate
increases in ceftazidime MICs, while maintaining high cefotaxime
MICs. It was proposed that D240G allows for better adaptation of
CTX-M producers to the concurrent exposure to both drugs.
Most probably, CTX-M-94 and -100 illustrate this phenomenon
in the evolution of the CTX-M-25-group enzymes.
The A77V substitution caused a two-fold increase in cefoxitin
MICs (2 vs. 4 mg/L) in CTX-M-94 and-100, and only a minor
increase in cefotaxime MICs (16 vs. 24 mg/L) in CTX-M-100. It
had no effect on the MICs of ceftazidime. In contrast to our
Figure 1. Comparison of the amino acid sequences of the novel CTX-M-25-group variants (CTX-M-94 and -100), with the known
CTX-M-25-group enzymes (CTX-M-25 and -39). Differences are highlighted in bold.
doi:10.1371/journal.pone.0046329.g001
Figure 2. Phylogenetic tree of CTX-M-25-group subtypes. Scale: amino acid substitutions per 100 residues.
doi:10.1371/journal.pone.0046329.g002
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results, Novais et al. observed a minor decrease in cefoxitin MICs
and a two-fold increase in MICs of cefotaxime and ceftazidime
after introducing A77V into CTX-M-15 [6]. These conflicting
outcomes might be explained by differences between CTX-M-1-
and -25- group enzymes in amino acid residues that line the highly
conserved active site. CTX-M-15, a prototypal CTX-M-1 group
enzyme, differs from CTX-M-94 and -100 at positions 103 (valine
and isoleucine, respectively) and 133 (valine and threonine,
respectively) that lie in the a structural domain of the CTX-M
enzyme and in close proximity to the V loop (based on the active
site structure described in Delmas et al. [30]. Finally, the A77V
substitution caused a two-fold decrease (MICs, 48 vs. 12 mg/L)
and a three-fold increase (MICs, 12 vs. 32 mg/L) in ceftriaxone
MICs in CTX-M-94 and -100, respectively.
Plasmid Typing
Replicon typing and HpaI plasmid profiling (Figure 3) revealed
that blaCTX-M-94 was located on a ,93 kb IncFI plasmid and
blaCTX-M-100 on a ,130 kb IncA/C plasmid. The blaCMY-2 gene,
which was also present in the CTX-M-94-producing isolate, was
located on a second ,98 kb IncI1 plasmid. The blaCTX-M-100-
harbouring plasmid was transferred to recipient cells with a high
efficiency (5.461022 per donor cell). On the other hand, the
blaCTX-M-94-carrying plasmid did not transfer. Instead, the blaCMY-
2-harbouring plasmid was transferred with an efficiency of
3.861022 per donor cell.
Genetic Environment of blaCTX-M Genes
Both blaCTX-M-94 and blaCTX-M-100 were located 36 bp down-
stream of ISEcp1, the most probable factor of mobilization of these
genes from the K. georgiana chromosome [31], and sequences
separating the genes from ISEcp1 were identical to each other.
Similar distances were previously reported for blaCTX-M-25 and
blaCTX-M-26 identified in Canada and the UK, respectively [8].
Interestingly, other blaCTX-M-25-like genes identified in Israel were
found to be located 126–128 bp downstream of ISEcp1 [11].
These findings suggest that CTX-M-94 and -100 might not have
emerged from other CTX-M-25-group members identified in
Israel so far, but from an independent ISEcp1-mediated mobili-
zation of a precursor K. georgiana gene.
This assumption seems to be further supported by the lack of
the direct association of blaCTX-M-94 and blaCTX-M-100 with a class
1 integron, demonstrated by a PCR-sequencing based class 1
integron analysis as described previously [11]. Unlike the above
mentioned blaCTX-M-25-like genes identified in Israel, which were
inserted into a class 1 integron [11], the ISEcp1-blaCTX-M-94 and
ISEcp1-blaCTX-M-100 transposition modules were not present in the
variable regions of the integrons identified in the blaCTX-M-94- and
blaCTX-M-100-containing plasmids. These integrons significantly
differed from each other. The one present on the plasmid with
blaCTX-M-94 harboured aacC1 (aminoglycoside acetyltransferase;
resistance to gentamicin), orfX (hypothetical protein), orfQ (hypo-
thetical protein) and aadA1 (aminoglycoside adenylyltransferase;
resistance to spectinomycin and streptomycin) gene cassettes, while
the one on the plasmid with blaCTX-M-100 harboured aadB
(aminoglycoside adenylyltransferase; resistance to gentamicin/
kanamycin/tobramycin), ereA (erythromycin esterase type 1;
resistance to erythromycin) and aadA1. For now, it is unclear
whether CTX-M-94 and -100 have emerged from each other or
from other CTX-M-25-group members by independent muta-
tional events. Because of limited publicly available sequence data,
it is not possible to make more global assumptions on the
evolutionary paths of the CTX-M-25-group enzymes.
Conclusions
This is the first report describing two novel ESBL variants of
the CTX-M-25-group, CTX-M-94 and -100, identified in two
E. coli isolates belonging to different clones, ST131 and ST88,
respectively. Both blaCTX-M-94 and blaCTX-M-100 were found
within ISEcp1 transposition units, located on ,93 kb non-
conjugative IncFI and ,130 kb conjugative IncA/C plasmids,
respectively. CTX-M-94 is the first CTX-M-25-group member
carrying leucine-119, which was shown here to be associated
with increased resistance to ceftriaxone. We have also confirmed
the role of the D240G substitution in the increase of enzyme
activity against ceftazidime in the context of the CTX-M-25-
type enzymes.
Figure 3. HpaI plasmid profiles of blaCTX-M-94-, blaCMY-2- and
blaCTX-M-100-harbouring plasmids. A 0.7% agarose gel was loaded
with HpaI restricted plasmid DNA purified from three recombinant E.
coli TOP10 strains containing the (A) blaCTX-M-94-, (B) blaCMY-2- and (C)
blaCTX-M-100-harbouring plasmids, respectively, and stained with GelRed.
Relative mobility calculations, based on known band sizes of the 1 Kb
DNA Extension Ladder (M), estimated total plasmid sizes to be (A)
93 kb, (B) 98 kb and (C) 130 kb.
doi:10.1371/journal.pone.0046329.g003
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